Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 31 July 2018, 20:30 HKT/SGT
Ascletis-developed Ganovo Acquired Extraordinary Achievement
Ganovo Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association

HONG KONG, July 31, 2018 - (ACN Newswire) - Ascletis announced on July 30, 2018 that the Ganovo phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association. Professor Wei Lai, the Director of the Institute of Hepatology of Peking University, also the principal investigator of Ganovo's clinical trial, was pleased to accept this award based on a unanimous vote by a professional reviewing committee convened by top national experts. The awarded paper won the highest scientific merits out of 577 conference papers submitted this year. Ganovo regimen demonstrated excellent results of a cure rate of 97 percent (SVR12) in genotype 1 non-cirrhotic patients, within a 12-week treatment duration.

Professor Wei Lai said, "This award showcased the outstanding recognition to Ganovo from the China Medical Association (CMA) and KOL's endorsement to China-driven self-innovation encouraged by the fast growth of the China bio-tech industry in recent years. As the first Direct-acting Anti-viral Agent (DAA) developed and launched successfully by a domestic company in China, Ganovo has shown excellent efficacy, better safety and tolerability. I sincerely hope Ganovo will make a larger impact and significant contribution to the elimination of HCV disease in China."

The National Congress of Chinese Society of the Infectious Disease is the largest and most influential academic conference in China. It attracted more than 2,000experts and doctors who participated in the conference this year from July 26-29. The award further reinforces the medical community's confidence in Ganovo's excellent efficacy, better safety and tolerability, strong commitment to high quality drugs, and service to Chinese patients delivered by Ascletis as a local innovative biotech company.

The Launching Conference for Gonovo, China's Indigenous Anti-hepatitis C Virus Innovative Drug was Held in Beijing

The launching conference for Ganovo (Danoprevir sodium tablets), China's indigenous anti-hepatitis C innovative drug was held at the China National Convention Center days ago. Such move has helped breaking the monopoly of Chinese the hepatitis C small molecular antiviral drugs by the international pharmaceutical giants.

Such drug has been developed by Ascletis Pharmaceutical (Zhejiang) Co., Ltd., a company dedicated to the development and commercialization of innovative drugs against hepatitis C virus (HCV), AIDS (HIV) and hepatitis B virus (HBV). Ascletis currently has five programs of antiviral drug discovery and development.

On June 8th, the Ascletis-developed Ganovo, China's first anti-hepatitis C class 1 innovative drug was launched with the approval by the China Food & Drug Administration. On June 27th, just 19 days later, Dr. Li Lanjuan, academician of the Chinese Academy of Engineering, director of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases and initiator of Shulan Healthcare, issued the first Ganovo prescription. According to the follow-up examinations, the hepatitis C virus RNA has not been detected during the one-month treatment of the patient.

At the launching conference for Ganovo product, Dou Xiaoguang, a professor at Shengjing Hospital of China Medical University, introduced the development process and characteristics of Ganovo (Danoprevir sodium tablets). She mentioned that the efficacy, resistance barrier and safety of Danoprevir are more advantageous than the Generation I, bringing hope for cure for hepatitis C patients in China.

Dr. Wu Jinzi, the specially-appointed expert of "the Recruitment Program of Global Experts", told reporters that the vision of the Ascletis is to become a world-class biotechnology company dedicated to meet the untapped medical needs in the three major areas of antiviral, cancer and fatty liver disease.

--- the source of the second part of the article is Xinhua News

July 31, 2018 20:30 HKT/SGT
Topic: Press release summary
Sectors: Daily News, BioTech
From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
Yidan Prize Conference Series: The Americas sets an outlook for innovation and evidence-based research in education  
May 24, 2019 17:00 HKT/SGT
Mitsubishi Motors Eclipse Cross Wins a String of Prestigious Awards in Russia  
May 24, 2019 16:35 HKT/SGT
Toyota Yaris WRC Tackles a Tough Gravel Double  
May 24, 2019 16:02 HKT/SGT
Sanli achieves revenue of S$71.4 million in FY2019  
May 24, 2019 10:00 HKT/SGT
WARC Media Awards 2019 open for entries  
May 23, 2019 22:00 HKT/SGT
Sanli achieves revenue of S$71.4 million in FY2019  
May 23, 2019 20:00 HKT/SGT
DENSO to Mass-produce Automotive Alternators Equipped with Newly Developed High-efficiency Diodes  
May 23, 2019 17:19 HKT/SGT
Tohoku University and DOCOMO Launch Research Project to Develop Artificial-intelligence Technology for Periodontal Disease Detection  
May 23, 2019 15:29 HKT/SGT
MHPS Receives Contract for Complete Renovation of Flue Gas Desulfurization System at the Dětmarovice Power Station in the Czech Republic  
May 23, 2019 14:15 HKT/SGT
The University of Tokyo, Toyota, and TRENDE to Begin Testing of Next-generation Electricity System  
May 23, 2019 13:03 HKT/SGT
More Press release >>
More >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: